Opinion|Videos|June 2, 2025
Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC
Panelists discuss how alectinib use in the adjuvant setting might shift sequencing strategies in metastatic ALK+ non–small cell lung cancer (NSCLC) and how resistance mutations influence post-frontline therapy selection.
Advertisement
Episodes in this series
Sequencing Strategies and Resistance Management
Key Themes:
- Impact of adjuvant alectinib use (ALINA) on sequencing strategies
- Selection of post-frontline therapies after ALK inhibitor progression
- Role of resistance mutations in therapy selection
- Emerging data on NVL-655 (from ESMO 2024)
Notable Insights:
- Dr Dietrich explored how adjuvant ALK inhibitor exposure might influence frontline metastatic therapy selection
Dr Lovly discussed strategies for selecting therapies after progression, including considerations of resistance mutations and data on NVL-655
Advertisement
Related to this article
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Inside the CAR T-Cell Therapy Process for CLL
5